Tag: androgen receptor inhibitor

Home / androgen receptor inhibitor

Categories

Darolutamide is approved by the USFDA for metastatic castration-sensitive prostate cancer

On June 3, 2025, the Food and Drug Administration (FDA) sanctioned darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA has...
androgen-receptor-inhibitor

Scan the code